Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Oncopeptides AB ( (SE:ONCO) ) just unveiled an update.
Oncopeptides AB has called its Annual General Meeting for 21 May 2026 in central Stockholm, offering shareholders the choice to attend in person or be represented by proxy. Shareholders must be registered in the Euroclear Sweden share register by 12 May 2026 and submit notice of participation no later than 15 May 2026, ensuring proper identification and, where relevant, supporting proxy documentation.
The company is also enabling participation through advance postal voting, using a dedicated form available on its website that must reach Oncopeptides by 15 May 2026. Nominee-registered shareholders are required to temporarily re-register their shares in their own names by 15 May 2026 to exercise voting rights, underscoring the company’s effort to facilitate broad shareholder engagement within Swedish corporate governance rules.
More about Oncopeptides AB
Oncopeptides AB is a Stockholm-based biopharmaceutical company focused on developing and commercializing therapies for cancer. The company targets hematological malignancies and solid tumors, operating within the oncology segment of the life sciences industry and serving both Swedish and international healthcare markets.
Average Trading Volume: 2,725,031
Technical Sentiment Signal: Sell
Current Market Cap: SEK539.1M
For a thorough assessment of ONCO stock, go to TipRanks’ Stock Analysis page.